Chengdu Huasun Technology Group Inc., Ltd. Class A
SSZSE:0007903.76
CNY
+0.06
(+1.62%)
ISIN
CNE0000001H5
Return %
Stock
S&P 500
1Y
-6.47
13.14
3Y
-25.98
80.78
5Y
-30.11
67.74
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Ming Liang Huang
- Full Time Employees
- 727
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 101, 1st Floor Chengdu SI China 611731
- IPO Date
- Mar 27, 1998
- Website
- huasungrp.com
- Similar Companies
- Business
- Chengdu Huasun Technology Group Inc., Ltd. operates primarily as a pharmaceutical company engaged in the research, development, production, and sale of traditional Chinese medicines, Western medicines, biopharmaceutical products, and health supplements. Its core product portfolio includes Sanqitongshu capsules, nasal relief oral solution, Vitacol oral solution, antipyretic oral solution, national class 1 new drugs, Licatin (iodine [131I] metuximab injection), voriconazole tablets, roxithromycin dispersible tablets, and phenbromalone capsules. The company also operates in related pharmaceutical technical services and consulting along with merchandise and property management consulting. Beyond pharmaceuticals, Chengdu Huasun is involved in the design and construction of steel structure buildings. Founded in 1988 and headquartered in Chengdu, China, the company evolved from the pharmaceutical factory affiliated with Chengdu University of Traditional Chinese Medicine and has been listed on the Shenzhen Stock Exchange since 1998. Recent major developments include the cancellation in mid-2024 of a previously planned acquisition of Sichuan Bohaoda Biotechnology Co., Ltd., which was valued at approximately CNY 1 billion. In 2025, Chengdu Huasun’s flagship product, Sanqitongshu capsules, received national secondary protection status as the first traditional Chinese medicine to do so, underscoring its strategic importance in the company's portfolio. The company is also actively streamlining its operations by reducing non-core construction projects to better allocate resources towards its pharmaceutical business. Financially, the company faced pressures in 2025 with reported declining revenues and net losses compared to previous years. Additionally, its subsidiary Xingrui Pharmaceutical sold a 5.4% stake in Shanghai Lingkai, signaling strategic portfolio adjustments. Chengdu Huasun’s operational footprint is primarily in China, with a focus on pharmaceutical markets targeting both traditional Chinese medicine and Western medicine consumers, as well as biopharmaceutical innovation. The firm is recognized for its significant contributions to pharmaceutical technology innovation, holding numerous awards including the National High-tech Industrialization Ten Year Achievement Award and rankings in national proprietary Chinese medicine industry lists. It maintains control under the umbrella of Yuanhong Technology and Xinghui Group subsidiaries, reflecting a broader corporate structure focused on growth within the pharmaceutical and healthcare sectors. This combination of traditional Chinese medicine expertise, biopharmaceutical innovation, and strategic operational adjustments highlights Chengdu Huasun Technology Group Inc., Ltd.'s positioning as a leading player in China’s pharmaceutical industry with ongoing efforts to optimize its business structure and product offerings.